Putting the award page together from the records…
Putting the award page together from the records…
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
15 actions since 2023-01-13. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-07-29 | P00026 | Supplemental agreement (work within scope) | $8.01M | BILATERAL NO-COST MODIFICATION EXTENDING POPS FOR CLINS 0003, 0007-0012; INCREASES CLIN 0012 BARDA FUNDING BY $8.009M AND GENENTECH COST SHARE BY $5.507M; TOTAL EXERCISED AGREEMENT VALUE INCREASED TO $251.709M. |
| 2026-03-26 | P00025 | Supplemental agreement (work within scope) | $0 | THE PURPOSE OF THIS NO COST MOD IS TO REVISE ARTICLE IV, TO UPDATE GENENTECH'S VOTER FOR ALTEPLASE AND TO MODIFY THE STATEMENT OF WORK TO UPDATE ELIMINATE SUBCLIN PERIOD OF PERFORMANCE DATES. |
| 2025-10-01 | P00024 | Administrative change | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO REVISE ARTICLE V, AGREEMENT ADMINISTRATION B, REPLACE THE GOVERNMENT POINTS OF CONTACT. |
| 2025-06-18 | P00023 | Administrative change | $0 | CORRECT POP DATES AND DELETE DELIVERY DATES |
| 2025-06-16 | P00022 | Supplemental agreement (work within scope) | $5.56M | MOD SOW FOR CLINS 0007, 0010, AND 0011 LEPB NONCLINICAL AND CLINICAL DEVELOPMENT, CLIN 0012 TRAUMATIC BRAIN INJURY (TBI) DIAGNOSTICS AND MONITORING. ADD FUNDING AND MODIFY SOW. MODIFY ARTICLE VI (COST SHARING): THE TOTAL VALUE OF COMMITTED FUNDS FROM |
| 2025-05-05 | P00021 | Supplemental agreement (work within scope) | $11.50M | THE PURPOSES OF THIS MODIFICATION ARE TO: 1. CLIN 0011 - LEPB NONCLINICAL AND CLINICAL DEVELOPMENT: ADD FUNDING OF $11,500,000.00 AND MODIFY THE STATEMENT OF WORK (SOW) TO SUPPORT CLINICAL AND NON-CLINICAL PHARMACOLOGY, RESISTANCE, AND SUSCEPTIBILI |
| 2025-01-10 | P00020 | Supplemental agreement (work within scope) | $8.70M | 1) CLIN 0003, ALTEPLASE SULFUR MUSTARD INDICATION. EXTEND THE PERIOD OF PERFORMANCE. 2) CLIN 0011 LEPB NONCLINICAL AND CLINICAL DEVELOPMENT. ADD SUPPLEMENTAL WITHOUT MODIFYING THE STATEMENT OF WORK. 3) CLARIFY COMPOSITION OF THE JOC AND ITS VOTERS. |
| 2024-10-11 | P00019 | Supplemental agreement (work within scope) | $0 | ADD LAURA SADDISON AS A NON-VOTING JOC MEMBER |
| 2024-09-26 | P00018 | Option exercised | $30.44M | EXERCISE CLIN 0012 FOR TBI DIAGNOSTIC AND MONITORING AND EXTEND CLIN 0009 COVASTIL PERIOD OF PERFORMANCE. |
| 2024-06-10 | P00017 | Funding only | -$8.83M | DE-OBLIGATE CANCELING FUNDS FROM CLIN 0003. |
| 2024-03-13 | P00016 | Supplemental agreement (work within scope) | $12.94M | SUPPLEMENTAL FUNDING, REVISE OTTR, AND REVISE STATEMENT OF WORK. |
| 2023-11-29 | P00015 | Administrative change | $0 | REVISE THE OTAO AND CORRECT PERIOD OF PERFORMANCES. |
| 2023-07-17 | P00014 | Supplemental agreement (work within scope) | $0 | GENENTECH UMBRELLA AGREEMENT - UPDATE CLIN 0008 POP AND UPDATE SOW |
| 2023-03-23 | P00013 | Supplemental agreement (work within scope) | $1.20M | GENENTECH UMBRELLA AGREEMENT |
| 2023-01-13 | P00012 | Supplemental agreement (work within scope) | $0 | GENENTECH UMBRELLA AGREEMENT |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-20). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗